COAG Overview

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company. The Company is developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. It designs its assets to address critical gaps in the treatment of coagulation disorders. Its lead asset, sutacimig (HMB-001), is a bispecific antibody in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Its second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. HMB-002 is designed to address the underlying biological drivers of Von Willebrand Disease by increasing endogenous levels of von Willebrand factor (VWF), and Factor VIII, a blood coagulation protein. It is also advancing multiple preclinical and discovery-stage assets.

Wall Street analysts forecast COAG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for COAG is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Hemab Therapeutics Holdings Inc revenue for the last quarter amounts to NaN USD, decreased

Hemab Therapeutics Holdings Inc. EPS for the last quarter amounts to USD, decreased

Hemab Therapeutics Holdings Inc (COAG) has 0 emplpoyees as of May 26 2026.

Today COAG has the market capitalization of 1.21B USD.